Type 2 Diabetes Treated With Insulin
Conditions
Keywords
Type 2 diabetes, C-peptide, beta-cell reserve, insulin use
Brief summary
C-peptide is used to evaluate beta cell reserves. Patients with type 2 diabetes are treated with insulin for different indications. Other than beta-cell insufficiency and organ failures, insulin treatment is needed for a specified period. The investigators want to evaluate beta cell reserves in patients with type 2 diabetes treated with insulin for at least six months to see if that is the case. The investigators also want to compare the characteristics of these patients according to their beta cell reserves.
Detailed description
In patients with type 2 diabetes, initiation of insulin therapy is indicated in several conditions such as severe insulin resistance, acute metabolic decompensations, surgery, pregnancy, and progression of diabetic complications, and also when glycemic control cannot be achieved with effective lifestyle regulation and non-insulin antidiabetic medications. Some of these indications are transient, and patients should be reassessed to choose the appropriate treatment options. Clinical inertia is one of the new topics expressed in the recent diabetes guidelines. The investigators aimed to investigate the beta cell reserves of the patients with type 2 diabetes who are treated with insulin, to see if they have insufficient insulin secretion and if not, to compare their characteristics.
Interventions
DIAGNOSTIC_TESTC-peptide concentrations
The patients will be grouped by their C-peptide concentrations
Sponsors
Goztepe Training and Research Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with type 2 diabetes who had been treated with insulin as a monotherapy or as a component of combination therapy for at least 6 months.
Exclusion criteria
* Diagnosis of other types of diabetes, * end-stage renal failure, * history of renal transplantation, * diabetic acute metabolic decompensation, * decompensated heart failure, * advanced liver disease, * pregnancy, * acute or chronic pancreatitis, * pancreatic carcinoma, * acute infections, * use of medications that might affect glucose regulation (e.g. corticosteroids)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of adequate, borderline and insufficient beta cell reserves assessed by the fasting C-peptide concentrations | 3 months | Fasting C-peptide concentrations will be measured in patients with type 2 diabetic patients using insulin as a monotherapy or as part of combination therapy and the patients will be grouped as patients with adequate beta cell reserves, patients with borderline beta cell reserves and patient with insufficient beta cell reserves. |
| Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings | 3 months | Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings, especially the components of metabolic syndrome. |
Countries
Turkey (Türkiye)
Outcome results
None listed